Akero Therapeutics AKRO Stock
Akero Therapeutics Price Chart
Akero Therapeutics AKRO Financial and Trading Overview
| Akero Therapeutics stock price | 20.76 USD |
| Previous Close | 55.17 USD |
| Open | 54.97 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1000 |
| Day's Range | 54.88 - 55.67 USD |
| 52 Week Range | 9.26 - 58.38 USD |
| Volume | 446.59K USD |
| Avg. Volume | 690.74K USD |
| Market Cap | 3.05B USD |
| Beta (5Y Monthly) | -0.933607 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.89 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 59.86 USD |
AKRO Valuation Measures
| Enterprise Value | 2.45B USD |
| Trailing P/E | N/A |
| Forward P/E | -17.199377 |
| PEG Ratio (5 yr expected) | 1.35 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 8.466493 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -20.778 |
Trading Information
Akero Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.933607 |
| 52-Week Change | 354.02% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 58.38 USD |
| 52 Week Low | 9.26 USD |
| 50-Day Moving Average | 45.44 USD |
| 200-Day Moving Average | 41.55 USD |
AKRO Share Statistics
| Avg. Volume (3 month) | 690.74K USD |
| Avg. Daily Volume (10-Days) | 688.21K USD |
| Shares Outstanding | 55.33M |
| Float | 43.83M |
| Short Ratio | 7.6 |
| % Held by Insiders | 8.30% |
| % Held by Institutions | 108.40% |
| Shares Short | 4.69M |
| Short % of Float | 8.72% |
| Short % of Shares Outstanding | 8.48% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.40% |
| Return on Equity (ttm) | -49.38% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -117815000 USD |
| Net Income Avi to Common (ttm) | -111835000 USD |
| Diluted EPS (ttm) | -2.6 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 343.22M USD |
| Total Cash Per Share (mrq) | 6.85 USD |
| Total Debt (mrq) | 25.87M USD |
| Total Debt/Equity (mrq) | 8.45 USD |
| Current Ratio (mrq) | 20.835 |
| Book Value Per Share (mrq) | 6.521 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -94273000 USD |
| Levered Free Cash Flow (ttm) | -56439752 USD |
Profile of Akero Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 601 Gateway Boulevard |
| ZIP | 94080 |
| Phone | 650 487 6488 |
| Website | https://www.akerotx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 41 |
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Q&A For Akero Therapeutics Stock
What is a current AKRO stock price?
Akero Therapeutics AKRO stock price today per share is 20.76 USD.
How to purchase Akero Therapeutics stock?
You can buy AKRO shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Akero Therapeutics?
The stock symbol or ticker of Akero Therapeutics is AKRO.
Which industry does the Akero Therapeutics company belong to?
The Akero Therapeutics industry is Biotechnology.
How many shares does Akero Therapeutics have in circulation?
The max supply of Akero Therapeutics shares is 73.66M.
What is Akero Therapeutics Price to Earnings Ratio (PE Ratio)?
Akero Therapeutics PE Ratio is now.
What was Akero Therapeutics earnings per share over the trailing 12 months (TTM)?
Akero Therapeutics EPS is -2.89 USD over the trailing 12 months.
Which sector does the Akero Therapeutics company belong to?
The Akero Therapeutics sector is Healthcare.
Akero Therapeutics AKRO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2060.1 USD — |
-1.99
|
— — | 2051.95 USD — | 2093.4 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}